Who is sponsoring NCT05203185?

NCT05203185 is sponsored by NYU Langone Health.

What drugs are being tested in NCT05203185?

Interventions in NCT05203185: Pulmonary Embolism Risk Kalculator (PERK).

What condition does NCT05203185 study?

NCT05203185 studies Pulmonary Embolism.

Is NCT05203185 still recruiting?

NCT05203185 is currently completed. Last updated 26 June 2023.

Are results published for NCT05203185?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-06-26 · How we verify

NCT05203185

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nudging Provider Adoption of Clinical Decision Support

Completed NA Results posted Last updated 26 June 2023

What this trial tests

NA trial testing Pulmonary Embolism Risk Kalculator (PERK) in Pulmonary Embolism in 1,612 participants. Completed in 30 April 2022.

Timeline

1 July 2021

Primary endpoint
30 April 2022

30 April 2022

Quick facts

Lead sponsor	NYU Langone Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	1,612
Start date	1 July 2021
Primary completion	30 April 2022
Estimated completion	30 April 2022
Sites	2 locations across United States

Drugs / interventions tested

Pulmonary Embolism Risk Kalculator (PERK)

Conditions studied

Pulmonary Embolism — all drugs for Pulmonary Embolism →

Sponsor

NYU Langone Health — full company profile →

Who can join

Adults 25 to 70, any sex, with Pulmonary Embolism. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Patient Visits Where the Provider Adopted the Pulmonary Embolism Risk Kalculator (PERK) Tool Primary · Up to Month 6

The tool is considered adopted during a patient visit if the provider accepted the recommendation given by the PERK tool (i.e., a D-dimer was recommended and ordered or a CT pulmonary angiogram (CTPA) was recommended and ordered). This outcome measure is assessed using electronic health record (EHR) data from the patient visit.

Group	Value	95% CI
Intervention Site - Patients and Providers	39.11
No Intervention Site - Patients and Providers	20.66

Percentage of PE-Designated CTPA Tests That Are Positive for PE Secondary · Up to Month 6

Monitored using EHR reporting data. Calculated as the percentage of CTPA tests ordered to evaluate for PE that are positive for PE.

Group	Value	95% CI
Intervention Site - Patients and Providers	26.45
No Intervention Site - Patients and Providers	10.76

Sponsor's own description

The central hypothesis of this proposal is that the addition of a theory-informed "nudge" to a clinical decision support (CDS) tool will address identified behavioral barriers to use and significantly improve adoption by providers. Nudges are applications of behavioral science, defined as positive reinforcement and indirect suggestions that have a non-forced effect on decision making. This study will use a behavioral theory-informed process to develop a new CDS tool that includes a nudge that addresses barriers to adoption.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of a behavioral nudge on adoption of an electronic health record-agnostic pulmonary embolism risk prediction tool: a pilot cluster nonrandomized controlled trial.
Richardson S, Dauber-Decker KL, Solomon J, Seelamneni P, et al · · 2024 · cited 2× · PMID 39091509 · DOI 10.1093/jamiaopen/ooae064

Verify or expand the search:

Other recruiting trials for Pulmonary Embolism

Currently open trials in the same condition.

NCT07381712 — High-Flow Nasal Cannula Versus Non-Invasive Ventilation for Acute Respiratory Failure in Pulmonary Embolism. · NA · active not recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT07003646 — Reperfusion Treatment in Acute Pulmonary Embolism · recruiting
NCT06600542 — Inari VISION Registry · recruiting
NCT06622876 — Incidental Discovery of Pulmonary Emboli Via CT Scan: Impact of Detections on Patient Care and Resulting Complications · recruiting

Other NYU Langone Health trials

Trials by the same sponsor.

NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05203185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
Last refreshed: 26 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05203185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing